Droperidol
Butyrophenone Derivatives
- Drug class
- Butyrophenone Derivatives
- Availability
- Prescription only
- Routes
- Intramuscular, Intravenous
- Markets covered
- 2
- Products on record
- 3
- FDA reports (12 mo)
- 102
Overview
Droperidol is an active pharmaceutical ingredient in the Butyrophenone Derivatives group (N05AD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 15, 2026 |
| US United States | FDA | 1 | March 20, 2023 |
GBUnited Kingdom· MHRA
2 products
Uses
Prevention and treatment of post-operative nausea and vomiting (PONV) in adults and, as second line, in children (2 to 11 years) and adolescents (12 to 18 years). Prevention of nausea and vomiting induced by morphine and derivatives during post- operative patient controlled analgesia (PCA) in adults.
4.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Droperidol Injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.
How to take
Drug interactions
Known interactions involving Droperidol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 493. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL154130072 · revised May 15, 2026
- [2]FDA DailyMed · 147e033d-d997-4e… · revised March 20, 2023 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.